stroke, brain injure, elder dementia, sudden deafness, brain arteriospasm, central embolism of retinal artery, etc.
Conditions
Interventions
1:Each subject received in random order, single oral dose of 20, 40 or 60 mg ifenprodil tablets in cycle. The interval for washout period of 3 times administration was 7 days.
2:9 Chinese subjects were enrolled in the multiple-dose group of the PK study, and each of them was administered ifenprodil 20 mg orally thrice daily for 6 days.
Sponsors
Southwest Hospital, the Third Military Medical University, China
Eligibility
Sex/Gender
Male
Age
20 Years to 25 Years
Inclusion criteria
Inclusion criteria: (1) Body mass index(BMI) of 19 to 24 kg/m2 (inclusive); (2) No smoking, drinking or drug addiction before or during the study; (3) No history of cardiovascular, renal, gastrointestinal, hepatic, nervous,psychological disease or metabolic disorders.
Exclusion criteria
Exclusion criteria: if they had been enrolled in another pharmacokinetic study, had donated blood or had been given other drugs for some therapeutic courses during the last 3 months; or used caffeine-containing drink within 24 hours before the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the concentration of ifenprodil in human plasma; | — |
Countries
China
Contacts
Public ContactYongchuan Chen
Outcome results
None listed